Augmedix

Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Augmedix reports record Q4 earnings, eyes growth in healthcare tech

Augmedix demonstrated robust performance in Q4 2022 with strong revenue growth and bookings.
The company's strategic focus on product development and expansion into new markets bodes well for future growth.
While facing challenges in expenses and competition, Augmedix's opportunities for growth are significant.
Investors can be optimistic about Augmedix's outlook given its solid financial performance and growth prospects.

Augmedix reports robust Q1 growth, eyes profitability amid rising expenses

Augmedix demonstrated strong revenue growth, customer retention, and cost management in Q1 2023.
While facing challenges such as increasing expenses and cash outflows, the company remains focused on achieving profitability.
With a solid financial position and growth opportunities ahead, Augmedix is poised for continued success in the healthcare technology sector.

Augmedix reports robust Q2 growth, raises revenue guidance for 2023

Augmedix's Q2 performance reflects strong revenue growth, margin expansion, and strategic partnerships driving market positioning. While facing challenges in managing expenses and achieving profitability, the company remains optimistic about its growth trajectory. Augmedix's focus on innovation and capacity expansion positions it well to capitalize on opportunities for sustained revenue growth and market competitiveness.

Augmedix reports strong Q3 earnings, introduces AI app for clinicians

Augmedix demonstrated robust financial growth and operational improvements in Q3 2023, positioning itself for continued success.
The company's innovative product offerings and strategic partnerships underscore its commitment to driving healthcare efficiency.
While facing challenges such as product adoption ramp-up and regulatory compliance, Augmedix remains focused on growth and innovation.

Augmedix reports robust Q4 earnings, eyes growth in healthcare tech

Augmedix's strong financial performance in Q4 2023 reflects revenue growth, improved EBITDA, and strategic cost management, positioning the company for future success.
Diverse product offerings, positive partnerships, and efficient capital deployment are key strengths driving Augmedix's growth trajectory and market competitiveness.
While facing profitability challenges and the need for revenue diversification, Augmedix has significant opportunities in the expanding healthcare technology market and strong market demand for its products.

Augmedix reports robust Q1 growth, eyes AI-first SaaS transition

Augmedix's Q1 performance reflects strong revenue growth and strategic product launches, despite challenges in revenue outlook and increased expenses.
The company's focus on transitioning to an AI-first SaaS model and leveraging partnerships like HCA Healthcare positions it for future growth.
Optimism about clinical adoption and a commitment to reaching cash flow breakeven by 2025 highlight Augmedix's long-term strategic vision.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO, July 26, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (OTCQX: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced the company will be participating in the upcoming D.A. Davidson Bison Select Conference.

Augmedix to Present at the D.A. Davidson Bison Select Conference

SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (OTCQX: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced the company will be participating in the upcoming LD Micro Invitational XI investor conference.

Augmedix to Present at the 2021 LD Micro Invitational XI

SAN FRANCISCO, May 13, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (OTCQX: AUGX), a leading provider of remote medical documentation and live clinical support, today reported financial results for the three months ended March 31, 2021.

Augmedix Reports First Quarter 2021 Financial Results

News for Augmedix Stock (AUGX)